Terrence Blaschke
Academic Appointments
- Emeritus Faculty, Acad Council, Medicine - Clinical Pharmacology
Key Documents
Contact Information
- Academic Offices
Personal Information Email Tel (650) 725-4632
Professional Overview
Administrative Appointments
- Assistant Dean for Medical Student Advising, Stanford University School of Medicine (2006 - present)
- Associate Dean for Medical Student Advising, Stanford University School of Medicine (2002 - 2006)
Honors and Awards
- Oscar B. Hunter Award, American Society for Clinical Pharmacology and Therapeutics (ASCPT) (2007)
- Henry W. Elliott Distinguished Service Award, American Society for Clinical Pharmacology and Therapeutics (ASCPT) (2006)
- Honorary Fellowship, American College of Clinical Pharmacology (2004)
- Rawls-Palmer Progress in Medicine Lecture and Award, American Society for Clinical Pharmacology and Therapeutics (2002)
- Henry J. Kaiser Award for Outstanding Contributions to Medical Education, Stanford University School of Medicine (1999)
Professional Education
| B.S.: | University of Denver, Honors Program, Mathematics (1964) |
| M.D.: | Columbia University, P&S, Medicine (1968) |
Graduate & Fellowship Program Affiliations
Community and International Work
- AMPATH Program, Eldoret, Kenya
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
My ongoing Stanford research activities involve studies on the clinical pharmacology of drugs used in HIV-infected patients.
A focus of my laboratorys efforts in investigating drugs used in HIV-infected patients is to optimize the individual benefit/risk of pharmacotherapy of HIV or opportunistic infections by discovering and quantifying the pharmacokinetics and pharmacodynamics (PK/PD) of drugs used in such therapy; i.e., the distribution of individual-specific dose-concentration-effect relationships in the population. My laboratory has a special interest in understanding the relationships between antiviral drug exposure and virologic and toxicological responses. In the past this has lead to studies examining drug-taking behavior in these patients, since exposure is a function of both individual variability in pharmacokinetics and individual patterns of drug-taking behavior.
At the present time, my interests in HIV are in the access and quality of antiretroviral drugs for patients from less developed countries. The use of substandard drugs carries a high risk of promoting drug resistant variants of HIV, which could have widespread consequences over the long term. Another interest is drug-drug interactions between antiretroviral drugs and drugs used to treat opportunistic infections, in particular drugs used to treat tuberculosis.
Publications
- Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012: 275-301
- Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010; (4): 457-9
- Global challenges for clinical pharmacology in the developing world. Clin Pharmacol Ther. 2009; (6): 579-81
- Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes. Curr Opin HIV AIDS. 2008; (6): 603-7
- Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin. Am J Ther. 2007 Sep-Oct; (5): 427-34
- Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. J Pharmacokinet Pharmacodyn. 2007; (1): 35-55
Help